ADVITOS GmbH develops the CE-certified and worldwide patented ADVOS therapy (ADVanced Organ Support) — the first therapy for multi-organ support integrated in a single device. The ADVOS procedure improves patient survival by simultaneously supporting the three main detoxification organs of the human body: liver, lungs and kidneys. The therapy provides fluid-based removal of water-soluble toxins (kidney), protein-bound toxins (liver, kidney), and CO2 (lung). In addition, ADVOS enables rapid correction of acid-base balance through targeted alteration of blood pH. ADVOS therapy is used in intensive care units at 20 leading hospitals throughout Germany and is on its way to permeate the international market as well. ADVITOS GmbH receives funding from the European Union’s Horizon 2020 research and innovation program.